找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia; W. Hiddemann,R. Mertelsmann Conference proceedings 1990 Springer-V

[复制链接]
查看: 43410|回复: 38
发表于 2025-3-21 17:27:44 | 显示全部楼层 |阅读模式
书目名称New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia
编辑W. Hiddemann,R. Mertelsmann
视频video
图书封面Titlebook: New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia;  W. Hiddemann,R. Mertelsmann Conference proceedings 1990 Springer-V
描述Since the introduction of new anthracycline derivatives and anthrachi­ none analogues a few years ago, aclacinomycin A (Aclarubicin) has become an established agent for the treatment of hematologic malig­ nancies. A special symposium was therefore held during the congress of the German Society of Hermatology and Oncology in Hannover in October 1989 to provide an up-to-date overv.iew. Leading experts from the United States, Sweden, and Germany reported on the results being obtained with aclacinomycin A, alone or combined with other agents, in patients with acute leukemias and myelodysplastic syndromes. This book is based on their contributions. As regards single-agent treatment, aclacinomycin A in myelodys­ plastic syndromes is dealt with, as well as its application in older patients with acute myeloid leukemia. Four contributions are devoted to the use of aclacinomycin A in combination with conventional or intermediate­ dose cytosine arabinoside or etoposide in patients with relapsed or refractory acute myeloid leukemia. The results reported indicate that aclacinomycin A has substantial activity in the treatment of hematologic malignancies. In summary, this book provides a valuable
出版日期Conference proceedings 1990
关键词Aclacinomycin A; Akute Leukämie; Myelodysplast; Onkologie; Syndrom
版次1
doihttps://doi.org/10.1007/978-3-642-75720-4
isbn_softcover978-3-540-52613-1
isbn_ebook978-3-642-75720-4
copyrightSpringer-Verlag Berlin Heidelberg 1990
The information of publication is updating

书目名称New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia影响因子(影响力)




书目名称New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia影响因子(影响力)学科排名




书目名称New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia网络公开度




书目名称New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia网络公开度学科排名




书目名称New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia被引频次




书目名称New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia被引频次学科排名




书目名称New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia年度引用




书目名称New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia年度引用学科排名




书目名称New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia读者反馈




书目名称New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia读者反馈学科排名




单选投票, 共有 0 人参与投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 20:52:19 | 显示全部楼层
发表于 2025-3-22 00:41:41 | 显示全部楼层
发表于 2025-3-22 07:42:53 | 显示全部楼层
Low-Dose Aclacinomycin and Intermediate-Dose Cytosine Arabinoside in Relapsed and Refractory Acute or 5 days) and intermediate-dose cytosine arabinoside (Ara-C 1 g/m. twice daily for 4 days). Most patients had received previous therapy with high- or intermediate-dose Ara-C plus mitoxantrone (HAM, IAM) and TAD (6-thioguanine, standard-dose cytosine arabinoside, and daunorubicin). Four patients had
发表于 2025-3-22 12:13:43 | 显示全部楼层
发表于 2025-3-22 13:22:44 | 显示全部楼层
发表于 2025-3-22 20:01:07 | 显示全部楼层
发表于 2025-3-22 23:41:36 | 显示全部楼层
发表于 2025-3-23 04:16:21 | 显示全部楼层
发表于 2025-3-23 07:54:00 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-14 10:26
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表